Irish medical group recommends boycott of Teva drugs, citing Gaza conflict
The move could affect 12.5% of prescriptions in the country, prompting Teva to defend its role in the local healthcare system.
By Sergio Ramirez ·

The Irish Hospital Consultants Association voted last week to recommend a boycott of Teva Pharmaceuticals medicines. The professional body urged its members to avoid prescribing, administering, or using the Israeli company's products whenever clinically appropriate and equivalent alternatives are available.
The recommendation carries substantial weight in the Irish healthcare system. Teva accounts for approximately 12.5 percent of all prescriptions in Ireland. One in every eight prescription packs supplied to local pharmacies is a Teva medicine. The motion specifies that the preference should not compromise patient safety, treatment continuity, or clinical outcomes.
Teva expressed disappointment in a statement sent to The Jerusalem Post on Sunday. The company has manufactured medicines in Ireland for more than thirty years and serves as one of the largest suppliers to the Health Service Executive. Teva argued that healthcare decisions should rely on clinical evidence and patient needs rather than political factors.
The association cited ethical concerns regarding Teva's operations in the context of the ongoing conflict in Gaza. The motion states that the organization will support and defend clinicians who choose to avoid the products for ethical reasons. This follows recent actions by the UK’s Royal College of Nursing and the Royal College of Pharmacy, which ended commercial partnerships with Teva UK weeks ago without calling for a full product boycott.
Thomas Donnelly, a pediatric orthopedic surgeon, introduced the proposal. He has treated families from Gaza and described their injuries as devastating and requiring lifelong management. Donnelly said he could not use Teva products in good conscience where a clinically appropriate alternative exists. He described the use of products that could indirectly contribute to further bombardments as unconscionable.
Teva warned that restricting access to medicines for reasons unrelated to patient care risks undermining the principle that individuals receive the most appropriate treatment. The company stated it remains committed to working constructively with healthcare professionals across Ireland to ensure a consistent supply of high-quality medicines.
The motion passed with the explicit condition that patient safety remains the primary guide. The association's stance reflects a growing trend among medical professionals in Ireland and globally to question the procurement of Teva products when other options are on the table.






